Alkermes ALKS Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Axsome TherapeuticsAXSM

$23.01M-5.5%

Indivior Pharmaceuticals, Inc.INDV

$32M-23.8%

LBR

LB Pharmaceuticals IncLBRX

$3.47M—

Harmony Biosciences Holdings, Inc.HRMY

$5.8M+225%

Neurocrine BiosciencesNBIX

$463.5M-6.0%

Mirum Pharmaceuticals, Inc.MIRM

$12.87M+29.2%

FAQ

What is Alkermes's operating lease liabilities (total)?

Alkermes (ALKS) reported operating lease liabilities (total) of $69.45M in Q2 2026.

How has Alkermes's operating lease liabilities (total) changed year-over-year?

Alkermes's operating lease liabilities (total) decreased by 4.4% year-over-year, from $72.68M to $69.45M.

What is the long-term trend for Alkermes's operating lease liabilities (total)?

Over 5 years (2020 to 2025), Alkermes's operating lease liabilities (total) has grown at a -12.3% compound annual growth rate (CAGR), from $135.2M to $70M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.